An update on the management of chronic lymphocytic leukaemia

Bibliography

• DIEHL L, KAMEL L, MENCK H: The national cancer data base report of age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer (1999) 86:2684–2692.
   PubMed Web of Science ®Google Scholar
• US CANCER STATISTICS WORKING GROUP: United States Cancer Statistics: 2000 Incidence. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute (2003).
   Google Scholar
• RAI KR, SAWITSKY A, CRONKITE EP et al.: Clinical staging of chronic lymphocytic leukemia. Blood (1975) 46:219–234.
   PubMed Web of Science ®Google Scholar
• BINET JL, AUQUIER A, DIGHIERO G et al.: A new prognostic classification of chronic lymphocytic leukemia derived from multivariate survival analysis. Cancer (1981) 48:198–206.
   PubMed Web of Science ®Google Scholar
• CHESON BD, BENNETT JM, GREVER M et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 87:4990–4997.
   PubMed Web of Science ®Google Scholar
• ••Standardised criteria for the diagnosisand treatment of CLL.
   Google Scholar
• DIGHIERO G, MALOUM K, DESABLENS B et al.: Chlorambucil in indolent chronic lymphocytic leukemia. N. Engl. Med. (1998) 338:1506–1514.
   PubMed Web of Science ®Google Scholar
• DAMLE RN, WASIL T, FAIS F et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 94: 1840-1847.
   Google Scholar
• VASCONCELOS Y, DAVI F, LEVY V et al.: Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. Clin. Oncol. (2003) 21:3928–3932.
   Web of Science ®Google Scholar
• ORCHARD JA, IBBOTSON RE, DAVIS Z et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 363:105–111.
   PubMed Web of Science ®Google Scholar
• CLL TRIALISTS' COLLABORATIVE GROUP: Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. Natl. Cancer Inst. (1999) 91:861–868.
   Google Scholar
• JOHNSON S, SMITH AG, LOFFLER H et al.: Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet (1996) 347:1432–1438.
   PubMed Web of Science ®Google Scholar
• RAI KR, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. Med. (2000) 343:1750–1757.
   PubMed Web of Science ®Google Scholar
• ••As front-line therapy, fludarabine isassociated with superior response rates, remission duration, and progression-free survival in comparison to chlorambucil.
   Google Scholar
• LEPORRIER M, CHEVRET S, CAZIN B et al.: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood (2001) 98:2319–2325.
   PubMed Web of Science ®Google Scholar
• EICHHORST BE BUSCH R, STAUCH M et al.: Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a Phase III study of the German CLL Study Group (GCLLSG). Blood (2003) 102:109a (Abstract 369).
   Google Scholar
• DE CATALDO F, DELMER A, GANDRA et al.: A randomized Phase II trial of high-dose chlorambucil versus fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group. Hematol. Cell Ther. (1999) 41:127–136.
   PubMedGoogle Scholar
• LEVY V, PORCHER R, DELABARRE F et al.: Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. Clin. Epidemiol. (2001) 54:747–754.
   PubMed Web of Science ®Google Scholar
• TSENG WC, DERSE D, CHENG YC et al.: In vitro biological activity of 9-beta-D-arabinofuranosy1-2-fluoradenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. (1982) 21:474–477.
   PubMed Web of Science ®Google Scholar
• GANDHI V, KEMENA A, KEATING MJ et al.: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. (1992) 52:897–903.
   PubMed Web of Science ®Google Scholar
• EICHHORST BE BUSCH R, HOPFINGER G et al.: Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a Phase III study (CLL4 protocol) of the German CLL Study Group (GCLLSG). Blood (2003) 102:72a (Abstract 243).
   Google Scholar
• VVEISS MA, GLENN M, MASLAK P et al.: Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia (2000) 14:1577–1582.
   PubMed Web of Science ®Google Scholar
• FLINN IW, BYRD JC, MORRISON C et al.: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood (2000) 96:71–75.
   PubMed Web of Science ®Google Scholar
• ••FC regiment is highly active in lymphoidmalignancies.
   Google Scholar
• HALLEK M, SCHMITT B, WILHELM M et al: Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a Phase II study of the German CLL Study Group. Br. J. Haematol. (2001) 114:342–348.
   PubMed Web of Science ®Google Scholar
• SCHIAVONE EM, DE SIMONE M, PALMIERI S et al.: Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur.j Haematol. (2003) 71:23–28.
   PubMed Web of Science ®Google Scholar
• O'BRIEN SM, KANTARJIAN HM, CORTES J et al.: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Clin. Oncol. (2001) 19:1414–1420.
   Google Scholar
• ••FC regimen highly active in CLL.
   Google Scholar
• KEATING MJ, O'BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy for chronic lymphocytic leukemia. Clin. Oncol. (2004) (In Press).
   Google Scholar
• ••In addition to rituximab, FC significantlyincreases response rates, and quality.
   Google Scholar
• GONZALEZ H, MALOUM K, TEZENAS DU MONTCEL S et al.: Fludarabine and cyclophosphamide in chronic lymphoproliferative disorders. Blood (2003) 102:3576 (abstract 5153).
   Google Scholar
• CAZIN BE MALOUM K, CRETEIL MD et al.: Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL: final response and follow-up in 75 patients. Blood (2003) 102:438a (Abstract 1598).
   Google Scholar
• RUMMEL MJ, GAMM H, ROST A et al.: Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia - results of a randomized phase-III multicenter study. Blood (2003) 102:437a (Abstract 1591).
   Google Scholar
• TSIMBERIDOU AM, KEATING MJ, GILES FJ et al.: Fludarabine and mitoxantrone in patients with chronic lymphocytic leukemia. Cancer (2004) 100(12):2583–2591. FM is inferior to FCR in CLL.
   Google Scholar
• RUMMEL MJ, KAFER G, PFREUNDSCHUH M et al: Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter Phase II study. Ann. Omni (1999) 10:183–188.
   Google Scholar
• MORRISON VA, RAI KR, PETERSON BL et al.: Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Clin. Omni (2001) 19:3611–3621.
   PubMed Web of Science ®Google Scholar
• MORRISON VA, RAI KR, PETERSON BL et al.: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an Intergroup Study, Cancer and Leukemia Group B 9011. Clin. Oncol. (2002) 20:3878–3884.
   Web of Science ®Google Scholar
• TEFFERI A, LEVITT R, LI C-Y et al: Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia. Am. J. Clin. Oncol. (1999) 22:509–516.
   PubMed Web of Science ®Google Scholar
• TEFFERI A, LI C-Y, REEDER CB et al: A Phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia (2001) 15:1171–1175.
   PubMed Web of Science ®Google Scholar
• MAROTTA G, BIGAZZI C, LENOCI M et al.: Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica (2000) 85:1268–1270.
   PubMed Web of Science ®Google Scholar
• BOSCH F, FERRER A, LOPEZ-GUILLERMO A et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br: J. Haematol. (2002) 119:976–984.
   PubMed Web of Science ®Google Scholar
• SCHMITT BE FRANKE A, BURKHARD O et at Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: results of the first interim ananlysis of a Phase III study of the German CLL Study Group (GCLLSCG). Blood (2002) 100:3646 (Abstract 5015).
   Google Scholar
• GREVER MR, KOPECKY KJ, COLTMAN CA et al.: Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev Fr. Hematol. (1988) 30:457–459.
   PubMedGoogle Scholar
• HIDDEMANN W, ROTTMANN R, WORMANN B et al: Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a phase-II study. Ann. Hematol. (1991) 63:1–4.
   PubMed Web of Science ®Google Scholar
• PUCCIO CA, MITTELMAN A, LICHTMAN SM et al: A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J. Clin. Oncol. (1991) 9:1562–1569.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O'BRIEN S, KANTARJIAN H et al.: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single-agent. Blood (1993) 81:2878–2884.
   Google Scholar
• ••Long-term follow-up of fludarabine-treated CLL.
   Google Scholar
• KEMENA A, O'BRIEN S, KANTARJIAN H et al.: Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leak. Lymphoma (1993) 10:187–193.
   Google Scholar
• SORENSEN JM, VENA DA, FALLAVOLLITA A et al.: Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute. Clin. Omni (1997) 15:458–465.
   PubMed Web of Science ®Google Scholar
• ZINZANI PL, BENDANDI M, MAGAGNOLI M et al.: Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia. Haematologica (2000) 85:1135–1139.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O'BRIEN S, LERNER S et al.: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood(1998) 92:1165–1171.
   Google Scholar
• ROBERTSON LE, O'BRIEN S, KANTARJIAN H et at Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia (1995) 9:943–945.
   PubMed Web of Science ®Google Scholar
• MAURO FR, FOA R, MELONI G et al.: Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica (2002) 87:926–933.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O'BRIEN S, KONTOYIANNIS D et al.: Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma (2002) 43:1755–1762.
   Google Scholar
• GARCIA-MANERO G, O'BRIEN S, CORTES J et al.: Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood (2001) 98:633a (Abstract 2650).
   Google Scholar
• GENINI D, ADACHI S, CHAO Q et al: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting mitochondria. Blood(2000) 96:3537–3543.
   PubMed Web of Science ®Google Scholar
• STAIB P, SCHINKOTHE T, VOLIOTIS D et al.: Fludarabine induces secondary cross drug resistance in CLL. Blood (2001) 98:151a (Abstract 636).
   Google Scholar
• O'BRIEN S, KANTARJIAN H, ESTEY E et al.: Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl. J. Med. (1994) 330:319–322.
   Google Scholar
• SAVEN A, LEMON RH, PIRO LD: 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl. J. Med. (1993) 328:812–813.
   PubMed Web of Science ®Google Scholar
• DELANNOY A, HANIQUE G: 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. (1993) 328:812.
   PubMed Web of Science ®Google Scholar
• BYRD JC, PETERSON B, PIRO L et al.: A Phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia (2003) 17:323–327.
   PubMed Web of Science ®Google Scholar
• ••Cladribine therapy for fludarabine-refractory CLL.
   Google Scholar
• WEISS MA, MASLAK PG, JURIC JG et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J. Clin. Oncol (2003) 21:1278–1284.
   PubMed Web of Science ®Google Scholar
• WIERDA W, O'BRIEN S, FADERL S et al.: Improved survival in patients with relapsed - refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and ritwdmab (FCR) combination. Blood (2003) 102:110a (Abstract 373).
   Google Scholar
• KENNEDY B, RAWSTRON A, HAYNES A et al.: Eradication of detectable minimal disease with Campath-1H therapy results in prolonged survival in patients with refractory B-CLL. Blood (2001) 98:367a (Abstract 1544).
   Google Scholar
• KEATING MJ, FLINN I, JAIN V et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood(2002) 99:3554–3561.
   PubMed Web of Science ®Google Scholar
• ••Alemtuzurnab activity in advanced CLL.
   Google Scholar
• RAI KR, BYRD JC, PETERSON BL et al: A Phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901. Blood (2002) 100:205a (Abstract 772).
   Google Scholar
• FERRAJOLI A, O'BRIEN SM, CORTES JE et al.: Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer (2003) 98:773–778.
   Google Scholar
• LOZANSKI G, HEEREMA NA, FLINN IW et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood e-published January 15(2004).
   Google Scholar
• NABHAN C, PATTON D, GORDON LI et al.: Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Blood (2003) 102:361b (Abstract 5169).
   Google Scholar
• FADERL S, THOMAS DA, O'BRIEN S et al.: Experience with alemtuzumab plus ritwdmab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 101:3413–3415.
   Google Scholar
• ••Alemtuzurnab plus rituxirnab combinationtherapy in refractory lymphoid malignancies.
   Google Scholar
• BYRD JC, MURPHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Oncol (2001) 19:2153–2164.
   Google Scholar
• ••Rituximab dose intensity in CLL.
   Google Scholar
• O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. Clin. Oncol (2001) 19:2165-2170. Rituximab dose intensity in CLL.
   Google Scholar
• KENNEDY B, RAWSTRON A, CARTER C et al: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 99:2245–2247.
   PubMed Web of Science ®Google Scholar
• PETTITT AR: Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br. J. Haematol (2003) 121:692–702.
   PubMed Web of Science ®Google Scholar
• SAVEN A, LEMON RH, KOSTY M et al.: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. Clin. Oncol (1995) 13:570–574.
   Web of Science ®Google Scholar
• ••2-CDA activity in previouslyuntreated CLL.
   Google Scholar
• ROBAK T, BLO_SKI JZ, KASZNICKI Met al.: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood (2000) 96:2723–2729.
   Google Scholar
• ROBAK T, BLONSKI JZ, KASZNICKI M et al.: The efficacy and toxicity of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line therapy in patients with chronic lymphocytic leukemia (CLL) - updated results of a randomized multicenter study. Blood (2002) 100:386a (Abstract 1499).
   Google Scholar
• ROBAK T, BLONSKI JZ, KASZNICKI M et al.: Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. Br. J. Haematol (2000) 108:357–3686.
   PubMed Web of Science ®Google Scholar
• SAVEN A, CARRERA CJ, CARSON DA et al.: 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma (1991) 5(Suppl.):133–138.
   Google Scholar
• TALLMAN MS, HAKIMIAN D, ZANZIG C et al: Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. Clin. Oncol (1995) 13:983–984.
   Web of Science ®Google Scholar
• JULIUSSON G, LILIEMARK J: Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann. Oncol (1996) 7:373–379.
   PubMed Web of Science ®Google Scholar
• BRUGIATELLI M, HOLOWIECKA B, DMOSZYNSKA A et al.: 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. Ann. Hematol (1996) 73:79–84.
   PubMed Web of Science ®Google Scholar
• RONDELLI D, LAURIA F, ZINZANI PL et al.: 2-Chlorodeoxyadenosine in the treatment of relpased/refractory chronic lymphoprofiferative disorders. Eur.j Haematol (1997) 58:46–50.
   PubMed Web of Science ®Google Scholar
• BETTICHER DC, RATSCHILLER D, HSU SCHMITZ S-F et al.: Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Ann. Oncol. (1998) 9:721–726.
   Google Scholar
• RAT KR: Cladribine for the treatment ofhairy cell leukemia and chronic lymphocytic leukemia. Semin. Oncol (1998) 25:19-22. ao. VAN DEN NESTE E, LOUVIAUX I, MICHAUX JL et al.: Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia (2000) 14:1136–1142.
   Google Scholar
• MONTILLO M, TEDESCHI A, O'BRIEN S et al: Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer (2003) 97:114–120.
   PubMed Web of Science ®Google Scholar
• ROBAK T, GORA-TYBOR J, LECH-MARANDA E et al: Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Ear: Haematol (2001) 66:188–194.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, MICK R, MCINTYRE OR: Pentostatin in chronic lymphocytic leukemia: a Phase II trial of Cancer and Leukemia Group B. Clin. Oncol. (1989) 7:433–438.
   Web of Science ®Google Scholar
• HO AD, THALER J, STRYCKMANS P et al.: Pentostatin in refractory chronic lymphocytic leukemia: a Phase II trial of the European Organization for Research and Treatment of Cancer. Natl. Cancer Inst. (1990) 82:1416–1420.
   Google Scholar
• JOHNSON SA, CATOVSKY D, CHILD JA et al.: Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest. New Drugs (1998) 16:155–160.
   PubMed Web of Science ®Google Scholar
• THOMAS DA, O'BRIEN S, GILES FJ et al.: Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood (2001) 98:364a (Abstract 1533).
   Google Scholar
• DI GAETANO N, XIAO Y, ERBA E et al:Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. Haematol (2001) 114:800-809. aa. ALAS S, BONAVIDA B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bc1-2 and sensitization to cytotoxic drugs. Cancer Res. (2001) 61:5137–5144.
   Google Scholar
• SCHULZ H, KLEIN SK, REHWELD U et al.: Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood (2002) 100:3115–3120.
   PubMed Web of Science ®Google Scholar
• BYRD JC, PETERSON BL, MORRISON VA et al.: Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood (2003) 101:6–14.
   PubMed Web of Science ®Google Scholar
• ••FR regimen in CLL.
   Google Scholar
• KAY NE, LINT, CALL T et al.: Pentostatin combination therapy for untreated B-chronic lymphocytic leukemia. Blood (2003) 102:676a (Abstract 2504).
   Google Scholar
• BYRD JC, RAT KR, PETERSON BL et al: The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients. Blood (2003) 102:73a (Abstract 245).
   Google Scholar
• MAURO FR, GENTILE M, DE PROPRIS MS et al.: Postremissional rituximab administration for the treatment of older chronic lymphocytic leukemia (CLL) patients responsive to first line therapy with chlorambucil and prednisone. Blood (2003) 102:674a (Abstract 2497).
   Google Scholar
• LAMANNA N, WEISS MA, MASLAK PG et al.: Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL). Blood (2003) 102:440a (Abstract 1603).
   Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. I Clin. Oncol (1998) 16:2825–2833.
   PubMed Web of Science ®Google Scholar
• NGUYEN DT, AMESS JA, DOUGHTY H et al.: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoprofiferative disorders: evaluation of response on 48 patients. Ear. Haematol (1999) 62:76–82.
   PubMed Web of Science ®Google Scholar
• FORAN JM, ROHATINER AZ, CUNNINGHAM D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Clin. Oncol (2000) 18:317–324.
   Web of Science ®Google Scholar
• HUHN D, VON SCHILLING C, WILHELM M et al.: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 98:1326–1331.
   PubMed Web of Science ®Google Scholar
• ITALA M, GEISLER CH, KIMBY E et al: Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. Haematol. (2002) 69:129–134.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, BURRIS HA III, MORRISSEY LH et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood (2000) 95:3052–3056.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, LITCHY S, BARTON JH et al.: Single-agent rituximab as first-line and maintenance therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase IT trial of the Minnie Pearl Cancer Research Network. Clin. Oncol (2003) 21:1746–1751.
   Web of Science ®Google Scholar
• ••Rituximab single-agent induction andmaintenance therapy in CLL.
   Google Scholar
• DRAPKIN R, DI BELLA NJ, CUASAY LC et al.: Phase II multicenter trial of pentostatin and rituximab in patients with previously treated or untreated chronic lymphocytic leukemia. Blood (2002) 100:803a (Abstract 3171).
   Google Scholar
• ROBAK T, SMOLEWSKI P, URBANSKA-RYS H et al: Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Blood (2003) 102:2976 (Abstract 4912).
   Google Scholar
• EMMANOUILIDES C, LEONARD JP, SCHUSTER SJ et al: Multi-center, Phase II study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood (2003) 102:69a (Abstract 233).
   Google Scholar
• MAVROMATIS B, CHESON BD: Monoclonal antibody therapy of chronic lymphocytic leukemia. I Clin. Oncol (2003) 21:1874–1881.
   PubMed Web of Science ®Google Scholar
• GINALDI L, DE MARTINIS M, MATUTES E et al.: Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to CAMPATH-1H. Leak. Res. (1998) 22:185–191.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768–773.
   PubMed Web of Science ®Google Scholar
• ••Subcutaneous alemtuzumab in CLL.
   Google Scholar
• SKOTNICKI AB, ROBAK T, MAYER J et al.: Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (CAMPATH®, MABCAMPATH®) versus chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307). Blood (2003) 102:439a (Abstract 1599).
   Google Scholar
• PAT KR, BYRD JC, PETERSON BL et al: Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): Cancer and Leukemia Group B (CALGB) Study 19901. Blood(2003) 102:676a (Abstract 2506).
   Google Scholar
• VVENDTNER CM, RITGEN M, SCHWEIGHOFER CD et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL Study Group (GCLLSG). Blood (2003) 102:676a (Abstract 2503).
   Google Scholar
• PAT KR, FRETER CE, MERCIER RJ et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Clin. Oncol (2002) 20:3891–3897.
   Web of Science ®Google Scholar
• •• Alemtuzumab in fludarabine-treated CLL.
   Google Scholar
• RAI KR, KEATING MJ, COUTRE S et al: Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath9 on a compassionate basis. A report on efficacy and safety of CAM 511 trial. Blood(2002) 100:802a (Abstract 3165).
   Google Scholar
• PAT KR, COUTRE S, RIZZIERI D et al: The efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood (2001) 98:365a (Abstract 1538).
   Google Scholar
• CIOLLI S, GIGLI F, MANNELLI F et al: High response rates and reduced first-dose reactions with subcutaneous alemtuzumab in patients with relapsed and refractory CLL. Blood (2003) 102:3576 (Abstract 5156).
   Google Scholar
• FADERL S, ALBITAR M, WIERDA W et al.: Continuous I.V. infusion (c.i.) followed by subcutaneous (s.c.) alemtuzumab plus rituximab ia active in patients with relapsed/refractory chronic lymphoproliferative disorders (LPD). Blood (2003) 102:676a (Abstract 2505).
   Google Scholar
• WIERDA W, O'BRIEN S, FERRAJOLI A et al.: Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL. Blood (2003) 102:3606 (Abstract 5167).
   Google Scholar
• O'BRIEN SM, KANTARJIAN HM, THOMAS DA et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer (2003) 98:2657–2663.
   Google Scholar
• ••Alemtuzumab for residual disease in CLL.
   Google Scholar
• O'BRIEN SM, GRIBBEN JG, THOMAS DA et al.: Alemtuzumab for minimal residual disease in CLL. Blood (2003) 102:109a (Abstract 371).
   Google Scholar